Jazz Pharmaceuticals director gets 1,605 RSUs

Mulligan Seamus reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Mulligan Seamus reported acquisition or exercise transactions in this Form 4 filing.

Jazz Pharmaceuticals director Seamus Mulligan received an equity award covering 1,605 ordinary shares through restricted stock units under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. The units vest in full on July 23, 2027, subject to continuous service and conditions. After this award he holds 1,184,633 ordinary shares directly, plus 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.

Insider Trade Summary

Grant/Award: 1,605 shares

Grant/Award 2 txns

Insider Mulligan Seamus

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	1,605	$0.00	$0.00
holding	Ordinary Shares F2	--	--	--

Holdings After Transaction: Ordinary Shares — 1,184,633 shares (Direct); Ordinary Shares — 101,621 shares (Indirect, By Nerano Pharma Lim)

Footnotes (2)

1. F1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
2. F2. Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.

Key Figures

Restricted stock units granted: 1,605 shares Direct ordinary shares after award: 1,184,633 shares Indirect ordinary shares held: 101,621 shares +1 more

4 metrics

Restricted stock units granted 1,605 shares Equity award to director Seamus Mulligan on 2026-08-05

Direct ordinary shares after award 1,184,633 shares Direct holdings of Seamus Mulligan following RSU grant

Indirect ordinary shares held 101,621 shares Indirect holdings through Nerano Pharma Limited

RSU vesting date July 23, 2027 Date when 1,605 restricted stock units vest in full

Key Terms

restricted stock units, beneficially owned, Non-Employee Directors Stock Award Plan

3 terms

restricted stock units financial

"These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

beneficially owned financial

"Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Non-Employee Directors Stock Award Plan financial

"Granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Seamus Mulligan receive at Jazz Pharmaceuticals (JAZZ)?

Seamus Mulligan received 1,605 restricted stock units, each representing one ordinary share. The grant was made under Jazz Pharmaceuticals’ 2007 Amended and Restated Non-Employee Directors Stock Award Plan as part of his compensation as a non-employee director.

When do Seamus Mulligan’s new RSUs in Jazz Pharmaceuticals (JAZZ) vest?

The 1,605 restricted stock units vest in full on July 23, 2027. Vesting is contingent on Mulligan’s continuous service as a director and satisfaction of certain additional conditions specified in the stock award plan.

How many Jazz Pharmaceuticals (JAZZ) shares does Seamus Mulligan now hold directly?

Following the RSU grant, Seamus Mulligan directly holds 1,184,633 ordinary shares of Jazz Pharmaceuticals. This figure reflects his direct beneficial ownership after accounting for the newly awarded restricted stock units representing ordinary shares.

What indirect holdings in Jazz Pharmaceuticals (JAZZ) are attributed to Seamus Mulligan?

In addition to his direct stake, 101,621 ordinary shares are beneficially owned by Nerano Pharma Limited, an entity owned and controlled by Mulligan and his immediate family, and reported as his indirect holdings in Jazz Pharmaceuticals.

Are the new Jazz Pharmaceuticals (JAZZ) shares from Mulligan’s award immediately issued?

The award consists of restricted stock units, not immediately issued shares. Each unit represents a contingent right to receive one ordinary share, which will be delivered only when the units vest on July 23, 2027, subject to conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 05:42 PM Accepted by SEC EDGAR 08/07/2026 - 05:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mulligan Seamus

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/05/2026		A(1)		1,605	A	$0.0	1,184,633	D
Ordinary Shares								101,621	I	By Nerano Pharma Lim(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.

2. Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.

	By: /s/Paz Dizon, as attorney in fact For: Seamus Mulligan	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)